➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKinsey
Moodys
Express Scripts
Dow

Last Updated: August 3, 2020

DrugPatentWatch Database Preview

Litigation Details for AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2016)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc.
Biologic Drugs cited in AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc. (N.D. Cal. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-01-26 1 Complaint 10  U.S. Patent No. 6,642,245, entitled “Antiviral activity and resolution…years before Gilead obtained a patent on TAF, Gilead 11 had patented a similar prodrug called Tenofovir…weakness of the patents covering TAF, Gilead illegally seeks to 13 extend the period of patent exclusivity… The patents on TDF expire in 2017 and 2018. The impending expiration of the 23 TDF patents presented…was heavily reliant on the patent 24 exclusivity period of the TDF patents to prevent entry by generic External link to document
2016-07-06 108 Order on Motion to Dismiss 12 7,390,791 — “Prodrugs of phosphonate nucleotide Gilead … 9 patents (regardless of the patent owner) that it believes cover the … until the patent expires (if it has not already expired) or by stating that the patent is invalid or… constitutes an artificial act of patent infringement. If the patent owner initiates … PATENT PATENT OWNER External link to document
2016-03-21 34 Motion to Dismiss any of the patents identified in Count 1 of the Complaint including U.S. Patent No. 8,633,219.3 1n sum,…not JTI USA_as the owner of U.S. Patent No. 8,633,219 (the “‘219 Patent”). Nowhere is J T1 USA_identified…embodies a patent exhausts the patent holder’s rights and prevents the patent holder from invoking patent law…Exhibit C at p. 1. The official patent, obtained from the United States Patent and Trademark Office, clearly…alleged) that it has any. ‘219 Patent. The remaining patents set forth in the Complaint are alleged External link to document
2016-03-21 35 Request for Judicial Notice B - Gilead Form 10-K, # 3 Exhibit C - U.S. Patent 8,633,219)(Related document(s) 34 ) (Hoffman, Jerome External link to document
2016-04-11 50 Amended Complaint that enjoy the patent protections of not only 15 the TAF patents, but also the patents that cover the…years before Gilead obtained a patent on TAF, Gilead 11 had patented a similar prodrug called Tenofovir…weakness of the patents covering TAF, Gilead illegally seeks to 13 extend the period of patent exclusivity… The patents on TDF expire in 2017 and 2018. The impending expiration of the 22 TDF patents presented…was heavily reliant on the patent 23 exclusivity period of the TDF patents to prevent entry by generic External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Moodys
Dow
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.